• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Xenon Pharmaceuticals Inc.

    8/12/25 10:34:26 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XENE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Xenon Pharmaceuticals Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    98420N105

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    98420N105


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,146,462.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,174,761.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,174,761.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.8 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    98420N105


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,146,462.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,174,761.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,174,761.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.8 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    98420N105


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,146,462.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,174,761.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,174,761.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.8 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Xenon Pharmaceuticals Inc.
    (b)Address of issuer's principal executive offices:

    3650 Gilmore Way, Burnaby BC A1 V5G 48W
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    98420N105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    2.83  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
     
    Wellington Group Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
    Get the next $XENE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XENE

    DatePrice TargetRatingAnalyst
    5/7/2025$55.00Buy
    Chardan Capital Markets
    2/11/2025$67.00Buy
    Deutsche Bank
    10/10/2024$50.00Outperform
    Raymond James
    10/1/2024$53.00Buy
    H.C. Wainwright
    1/4/2024$62.00Buy
    Citigroup
    12/8/2023$63.00Outperform
    Robert W. Baird
    10/24/2023Overweight
    Cantor Fitzgerald
    4/25/2023$58.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $XENE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Xenon Pharmaceuticals Inc.

    SCHEDULE 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    8/12/25 10:34:26 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Xenon Pharmaceuticals Inc.

    10-Q - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

    8/11/25 4:32:31 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

    8/11/25 4:04:21 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Xenon Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $55.00

    5/7/25 8:39:12 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on Xenon Pharmaceuticals with a new price target

    Deutsche Bank initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $67.00

    2/11/25 7:18:40 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Xenon Pharmaceuticals with a new price target

    Raymond James resumed coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $50.00

    10/10/24 8:32:28 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Commercial Officer Cline Darren S

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    6/24/25 9:35:16 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Cline Darren S claimed no ownership of stock in the company (SEC Form 3)

    3 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    6/24/25 9:33:09 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Patou Gary

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    6/6/25 6:00:25 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xenon Reports Second Quarter 2025 Financial Results & Business Update

    – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializ

    8/11/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon to Report Q2 2025 Financial Results on August 11, 2025

    VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, August 11, 2025. Conference Call/Webcast Information: Date: Monday, August 11, 2025Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Webcast: Pre-register hereDial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callersConference ID: 4102397    A live webcas

    8/4/25 8:01:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

    8/1/25 4:55:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Financials

    Live finance-specific insights

    View All

    Xenon Reports Second Quarter 2025 Financial Results & Business Update

    – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializ

    8/11/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon to Report Q2 2025 Financial Results on August 11, 2025

    VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, August 11, 2025. Conference Call/Webcast Information: Date: Monday, August 11, 2025Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Webcast: Pre-register hereDial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callersConference ID: 4102397    A live webcas

    8/4/25 8:01:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

    – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, anticipated in Q3 2025 – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-foc

    5/12/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Leadership Updates

    Live Leadership Updates

    View All

    Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

    VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Mr. Cline will lead commercial strategy and operations for the Company's portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy. Azetukalner is currently being studied in Phase 3 trials for the trea

    6/24/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

    – OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner – Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer – Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36 – Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy – New pre-clinical data shows Nav1.1 potentiator provides protection against

    12/6/24 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer

    VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule progr

    8/12/24 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc.

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    11/12/24 10:40:28 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    2/14/24 9:12:03 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    2/14/24 7:43:11 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care